Key Findings:  This study of pediatric patients with inflammatory bowel disease (IBD) identified an upregulation of CB2 receptors, suggesting a potential therapeutic target for drug discovery.
Type of Study:  Clinical Trial
Study Sample Size:  15
Study Result:  Positive
Research Location(s):  Italy
Year of Pub:  2022
Cannabinoids Studied:  Endocannabinoid (unspecified)
Phytocannabinoid Source:  Not Applicable
Receptors Studied:  CB2
Citation:  Strisciuglio C, et al. Increased expression of CB2 receptor in the intestinal biopsies of children with inflammatory bowel disease. Pediatr Res. 2023; 93:520-525. doi: 10.1038/s41390-022-02109-5
Authors:  Strisciuglio C, Creoli M, Tortora C, Martinelli M, Miele E, Paino S, Luongo L, Rossi F